Mga Batayang Estadistika
| CIK | 1850906 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Singular Genomics Systems, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 27, 2025 |
Singular Genomics Announces Closing of Acquisition by Deerfield Management EX-99.1 Exhibit 99.1 Singular Genomics Announces Closing of Acquisition by Deerfield Management February 21, 2025 SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affili |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2025 Singular Genomics Systems, Inc. (Exact name of registrant as specified in charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Comm |
|
| February 27, 2025 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SINGULAR GENOMICS SYSTEMS, INC. (a Delaware corporation) Singular Genomics Systems, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “GCL”), DOES HEREBY CERTIFY: 1. That the name of this corporation is Singular Genomics Systems, Inc., |
|
| February 27, 2025 |
AMENDED AND RESTATED BYLAWS SINGULAR GENOMICS SYSTEMS, INC. ARTICLE I Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SINGULAR GENOMICS SYSTEMS, INC. ARTICLE I OFFICES SECTION 1.1. Registered Offices; Other Offices. The registered office of the Corporation in the State of Delaware shall be in the City of Wilmington and County of New Castle. The Corporation may have such other offices, either within or outside of the State of Delaware, as the business of the Corporation m |
|
| February 21, 2025 |
As filed with the Securities and Exchange Commission on February 21, 2025 As filed with the Securities and Exchange Commission on February 21, 2025 Registration No. |
|
| February 21, 2025 |
As filed with the Securities and Exchange Commission on February 21, 2025 As filed with the Securities and Exchange Commission on February 21, 2025 Registration No. |
|
| February 21, 2025 |
As filed with the Securities and Exchange Commission on February 21, 2025 POS AM As filed with the Securities and Exchange Commission on February 21, 2025 Registration No. |
|
| February 21, 2025 |
As filed with the Securities and Exchange Commission on February 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on February 21, 2025 Registration No. |
|
| February 21, 2025 |
As filed with the Securities and Exchange Commission on February 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on February 21, 2025 Registration No. |
|
| February 21, 2025 |
As filed with the Securities and Exchange Commission on February 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on February 21, 2025 Registration No. |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 Singular Genomics Systems, Inc. (Exact name of registrant as specified in charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Comm |
|
| February 13, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) ( |
|
| January 15, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| December 31, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| December 31, 2024 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Singular Genomics Systems, Inc. |
|
| December 23, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER Among SINGULAR GENOMICS PARENT, LLC, SATURN MERGER SUB, INC. and SINGULAR GENOMICS SYSTEMS, INC. Dated as of December 22, 2024 TABLE OF CONTENTS Article 1 Definitions 3 1.1 Definitions 3 Article 2 The Merger 15 2.1 The Merger 15 2.2 Effective Time; Closing 15 2.3 Effect of the Merger 16 2.4 Certificate of Incorporation; Bylaws 16 2.5 Directors and Officers |
|
| December 23, 2024 |
Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of [•], is entered into by and among Singular Genomics Systems, Inc., a Delaware corporation (the “Company”), and [•], a [•] (the “Stockholder”). Capitalized terms used but not defined herein shall have the meanings given to them in the Merger Agreement (as defined below). RECITALS WHEREAS, con |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) ( |
|
| December 23, 2024 |
Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share Exhibit 99.1 Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share San Diego, CA. – December 23, 2024 - Singular Genomics Systems, Inc. (Nasdaq: OMIC) (“Singular Genomics” or the “Company”), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it has ent |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) ( |
|
| December 23, 2024 |
Exhibit 10.2 LIMITED GUARANTEE This Limited Guarantee, dated as of December 22, 2024 (this “Limited Guarantee”), is made by Deerfield Private Design Fund IV, L.P., a Delaware limited partnership, the “Guarantor”), in favor of Singular Genomics Systems, Inc., a Delaware corporation (the “Company”). Reference is hereby made to that certain Agreement and Plan of Merger, dated as of the date hereof (a |
|
| November 22, 2024 |
OMIC / Singular Genomics Systems, Inc. / CRCM LP - SC 13D/A Activist Investment SC 13D/A 1 sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82933R308 (CUSIP Number) Chun R. Ding c/o CRCM LP 475 Sansome Street, Suite 730 San Francisco, CA 941 |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 Singular Genomics |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) ( |
|
| November 12, 2024 |
Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results San Diego, CA, November 12, 2024 – Singular Genomics Systems, Inc. |
|
| November 5, 2024 |
OMIC / Singular Genomics Systems, Inc. / CRCM LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82933R308 (CUSIP Number) Chun R. Ding c/o CRCM LP 475 Sansome Street, Suite 730 San Francisco, CA 94111 (415) 578-5700 (Name, Address |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (C |
|
| November 1, 2024 |
OMIC / Singular Genomics Systems, Inc. / Flynn James E Activist Investment SC 13D/A 1 e663986sc13da-sgs.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 1)* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82933R308 ( |
|
| September 19, 2024 |
Singular Genomics Receives Non-Binding Acquisition Proposal from Concentra Biosciences and Tang Capital San Diego, CA, September 19, 2024 – Singular Genomics Systems, Inc. |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) |
|
| September 18, 2024 |
OMIC / Singular Genomics Systems, Inc. / TANG CAPITAL MANAGEMENT LLC Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the securities exchange act of 1934 (amendment no. |
|
| September 12, 2024 |
Joint Filing Agreement dated as of March 5, 2018 by and among the Reporting Persons.* EX-1 2 e663885ex1.htm Exhibit 1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including an |
|
| September 12, 2024 |
Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield San Diego, CA, September 12, 2024 – Singular Genomics Systems, Inc. |
|
| September 12, 2024 |
OMIC / Singular Genomics Systems, Inc. / Flynn James E Activist Investment SC 13D 1 e663885sc13d-sgs.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. )* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82933R308 (CUSI |
|
| September 12, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) |
|
| September 12, 2024 |
Non-binding Indication of Interest, submitted September 5, 2024* EX-3 3 e663885ex3.htm Exhibit 3 Deerfield Mgmt IV, L.P. Deerfield Management Company, L.P. Deerfield Private Design Fund IV, L.P. 345 Park Avenue South New York, NY 10010 September 4, 20241 Special Committee of Independent Directors Singular Genomics Systems, Inc. 3010 Science Park Road San Diego, CA 92121 Re: Non-Binding Indication of Interest Dear Special Committee of Independent Directors (the |
|
| August 13, 2024 |
Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results San Diego, CA, August 13, 2024 – Singular Genomics Systems, Inc. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 Singular Genomics Syst |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Co |
|
| August 7, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Com |
|
| August 7, 2024 |
3010 Science Park/Singular - Page 1 THIRD AMENDMENT TO LEASE AGREEMENT THIS THIRD AMENDMENT TO LEASE AGREEMENT (this “Third Amendment”) is made this 2 day of August, 2024 (the “Effective Date”), between ARE-SD REGION NO. |
|
| July 15, 2024 |
Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement San Diego, CA, July 15, 2024 – Singular Genomics Systems, Inc. |
|
| July 15, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Comm |
|
| June 27, 2024 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT to the AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of SINGULAR GENOMICS SYSTEMS, INC. Singular Genomics Systems, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST: The name of the Corporation is Singular Genomics Systems, Inc. The Amended a |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Comm |
|
| May 30, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Commi |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 Singular Genomics Sys |
|
| May 14, 2024 |
Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results San Diego, CA, May 14, 2024 – Singular Genomics Systems, Inc. |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Commi |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defin |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin |
|
| March 18, 2024 |
Calculation of Filing Fee Tables Calculation of Filing Fee Table Form S-8 (Form Type) Singular Genomics Systems, Inc. |
|
| March 18, 2024 |
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results San Diego, CA, March 18, 2024 – Singular Genomics Systems, Inc. |
|
| March 18, 2024 |
As filed with the Securities and Exchange Commission on March 18, 2024 As filed with the Securities and Exchange Commission on March 18, 2024 Registration No. |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-40443 Singular Genomics Systems, |
|
| March 18, 2024 |
Policy for Recovery of Erroneously Awarded Compensation. Exhibit 97.1 SINGULAR GENOMICS SYSTEMS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1. Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. This Policy is designed to comply with, and shall be interpreted to be consistent with, Secti |
|
| March 18, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Com |
|
| February 14, 2024 |
OMIC / Singular Genomics Systems, Inc. / Glezer Eli N. - SC 13G/A Passive Investment SC 13G/A 1 eg2024sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 82933R100 (CUSIP Number) December 31, 2023 (Date of |
|
| February 14, 2024 |
OMIC / Singular Genomics Systems, Inc. / Spaventa Andrew - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2024 |
OMIC / Singular Genomics Systems, Inc. / Flynn James E Passive Investment SC 13G/A 1 e619251sc13ga-sgs.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82933R100 (CUSIP Number) Decem |
|
| January 25, 2024 |
OMIC / Singular Genomics Systems, Inc. / Domain Partners IX, L.P. Passive Investment SC 13G/A 1 s13ga012524-singular.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Singular Genomics Systems, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 82933R |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (C |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Co |
|
| January 8, 2024 |
Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue EX-99.1 Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue San Diego, CA, January 7, 2024 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the four |
|
| November 14, 2023 |
AGREEMENT FOR TERMINATION OF LEASE This Agreement for Termination of Lease (this “Agreement”) is made and entered into as of July 19, 2023, by and between ARE-10933 NORTH TORREY PINES, LLC, a Delaware limited liability company (“Landlord”), and SINGULAR GENOMICS SYSTEMS, INC. |
|
| November 14, 2023 |
SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this "Second Amendment") is made as of May 7, 2020, by and between ARE-SD REGION NO. |
|
| November 14, 2023 |
FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this "First Amendment") is made as of February 24, 2020, by and between ARE. |
|
| November 14, 2023 |
FIRST AMENDMENT TO AGREEMENT FOR TERMINATION OF LEASE THIS FIRST AMENDMENT TO AGREEMENT FOR TERMINATION OF LEASE (this “First Amendment”) is made as of August 31, 2023, by and between ARE-10933 NORTH TORREY PINES, LLC, a Delaware limited liability company (“Landlord”), and SINGULAR GENOMICS SYSTEMS, INC. |
|
| November 14, 2023 |
Page 1 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) is made this 19 day of July, 2023 (the “Effective Date”), between ARE-SD REGION NO. |
|
| November 14, 2023 |
LEASE AGREEMENT THIS LEASE AGREEMENT (this "Lease") is made this 15 day of November, 2019, between ARE-SD REGION NO. |
|
| November 14, 2023 |
THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this "Third Amendment") is made as of June 19, 2020, by and between ARE-SD REGION NO. |
|
| November 14, 2023 |
Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results EX-99.1 Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results San Diego, CA, November 14, 2023 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quar |
|
| November 14, 2023 |
SIXTH AMENDMENT TO LEASE THIS SIXTH AMENDMENT TO LEASE (this “Sixth Amendment”) is made as of July 19, 2023, by and between ARE-SD REGION NO. |
|
| November 14, 2023 |
FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (this “Fourth Amendment”) is made as of April 20, 2021, by and between ARE-SD REGION NO. |
|
| November 14, 2023 |
FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this “Fifth Amendment”) is made as of January 19, 2022, by and between ARE-SD REGION NO. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) ( |
|
| November 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 |
|
| September 14, 2023 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2023 (September 13, 2023) Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdicti |
|
| August 14, 2023 |
OMIC / Singular Genomics Systems Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Com |
|
| August 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 Sing |
|
| August 9, 2023 |
Singular Genomics Reports Recent Highlights and Second Quarter 2023 Financial Results EX-99.1 Singular Genomics Reports Recent Highlights and Second Quarter 2023 Financial Results San Diego, CA, August 9, 2023 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quart |
|
| August 8, 2023 |
Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors EX-99.1 Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors San Diego, CA, August 8, 2023 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company’s Board of Director |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 (August 4, 2023) Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of in |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Comm |
|
| May 26, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Commi |
|
| May 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 Sin |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2023 |
Singular Genomics Reports Recent Highlights and First Quarter 2023 Financial Results EX-99.1 Singular Genomics Reports Recent Highlights and First Quarter 2023 Financial Results San Diego, CA, May 9, 2023 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter en |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defin |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-40443 Singular Genomics Systems, |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Comm |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. |
|
| March 2, 2023 |
Singular Genomics Systems, Inc. February 28, 2023 VIA ELECTRONIC MAIL Daralyn Durie [email protected] Re: Terms of Separation Dear Daralyn: This letter confirms the agreement (“Agreement”) between you and Singular Genomics Systems, Inc. (the “Company”) concerning the terms of your separation from employment and offers you certain benefits to which you would not otherwise be entitled, conditioned upo |
|
| March 2, 2023 |
Calculation of Filing Fee Tables Calculation of Filing Fee Table Form S-8 (Form Type) Singular Genomics Systems, Inc. |
|
| March 2, 2023 |
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2022 Financial Results EX-99.1 Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2022 Financial Results San Diego, CA, March 2, 2023 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the |
|
| February 14, 2023 |
OMIC / Singular Genomics Systems, Inc. / Spaventa Andrew - SC 13G/A Passive Investment SC 13G/A 1 d441685dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 82933R100 (CUSIP Number) December 31, 2022 (Date o |
|
| February 14, 2023 |
OMIC / Singular Genomics Systems, Inc. / Glezer Eli N. - SC 13G/A Passive Investment SC 13G/A 1 d442494dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 82933R100 (CUSIP Number) December 31, 2022 (Date o |
|
| February 14, 2023 |
OMIC / Singular Genomics Systems, Inc. / Revelation Alpine, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82933R100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 10, 2023 |
OMIC / Singular Genomics Systems, Inc. / Flynn James E Passive Investment SC 13G/A 1 e618268sc13ga-sgs.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82933R100 (CUSIP Number) Decem |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event Reported): January 9, 2023 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 9, 2023 |
Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2022 Revenue EX-99.1 2 d388770dex991.htm EX-99.1 Exhibit 99.1 Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2022 Revenue San Diego, CA, January 9, 2023 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and p |
|
| November 7, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 |
|
| November 7, 2022 |
Singular Genomics Reports Recent Highlights and Third Quarter 2022 Financial Results Singular Genomics Reports Recent Highlights and Third Quarter 2022 Financial Results San Diego, CA, November 7, 2022 ? Singular Genomics Systems, Inc. |
|
| November 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (C |
|
| November 7, 2022 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND is the type of information that the registrant treats as private and Confidential, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This First Amendment to Amended and Restated Loan and Se |
|
| October 4, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event Reported): September 30, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SINGULAR GENOMICS SYSTEMS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities |
|
| August 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 Sing |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Com |
|
| August 9, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266221 PROSPECTUS SUPPLEMENT (To Prospectus dated July 27, 2022) $100,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement and the accompa |
|
| August 9, 2022 |
Singular Genomics Reports Recent Highlights and Second Quarter 2022 Financial Results Singular Genomics Reports Recent Highlights and Second Quarter 2022 Financial Results San Diego, CA, August 9, 2022 ? Singular Genomics Systems, Inc. |
|
| July 25, 2022 |
Exhibit (d)(1) SINGULAR GENOMICS SYSTEMS, INC. 2021 EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED ON JULY 22, 2022) SINGULAR GENOMICS SYSTEMS, INC. 2021 EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED ON JULY 22, 2022) ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately upon its approval on May 19, 2021, although no Awards were granted under the Plan prior to the IP |
|
| July 25, 2022 |
Notice of Withdrawal of Election Form. Exhibit (a)(1)(D) INSTRUCTIONS TO NOTICE OF WITHDRAWAL OF ELECTION FORM If you previously elected to accept the offer by Singular Genomics Systems, Inc. |
|
| July 25, 2022 |
Exhibit (a)(1)(C) SINGULAR GENOMICS SYSTEMS, INC. 3010 Science Park Road San Diego, CA 92121 OPTION EXCHANGE - ELECTION FORM THIS OFFER AND YOUR WITHDRAWAL RIGHTS WILL EXPIRE AT 6:00 P.M., PACIFIC TIME, ON FRIDAY, AUGUST 19, 2022, UNLESS EXTENDED Before completing and signing this Election Form, we encourage you to read the documents that make up this tender offer, including (1) the Offer to Excha |
|
| July 25, 2022 |
Offer to Exchange Eligible Option(s) for New Option(s), dated July 25, 2022. Exhibit (a)(1)(A) SINGULAR GENOMICS SYSTEMS, INC. 3010 SCIENCE PARK ROAD SAN DIEGO, CALIFORNIA 92121 OFFER TO EXCHANGE ELIGIBLE OPTION(S) FOR NEW OPTION(S) JULY 25, 2022 SINGULAR GENOMICS SYSTEMS, INC. SUMMARY TERM SHEET - OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTION(S) FOR NEW OPTION(S) This offer and withdrawal rights will expire at 6:00 P.M., Pacific Time, on Friday, August 19, 2022, unless exten |
|
| July 25, 2022 |
2021 Equity Incentive Plan as amended and restated, and forms of agreements thereunder. EXHIBIT 10.1 SINGULAR GENOMICS SYSTEMS, INC. 2021 EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED ON JULY 22, 2022) SINGULAR GENOMICS SYSTEMS, INC. 2021 EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED ON JULY 22, 2022) ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately upon its approval on May 19, 2021, although no Awards were granted under the Plan prior to the IPO |
|
| July 25, 2022 |
Form of Email Notice Regarding Rejection of Options for Exchange. Exhibit (a)(1)(I) FORM OF EMAIL NOTICE REGARDING REJECTION OF OPTIONS FOR EXCHANGE From: SINGULAR GENOMICS SYSTEMS, INC. |
|
| July 25, 2022 |
Form of Announcement Email to Eligible Holders. Exhibit (a)(1)(B) FORM OF ANNOUNCEMENT EMAIL TO ELIGIBLE HOLDERS Subject: Singular Genomics Systems, Inc. |
|
| July 25, 2022 |
July 25, 2022 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| July 25, 2022 |
SC TO-I 1 d363074dsctoi.htm SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SINGULAR GENOMICS SYSTEMS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Cla |
|
| July 25, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Schedule TO (Form Type) Singular Genomics Systems, Inc. |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event Reported): July 22, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event Reported): July 22, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 25, 2022 |
Form of Reminder Email to Eligible Holders Regarding the Expiration of the Exchange Offer. Exhibit (a)(1)(G) FORM OF REMINDER EMAIL TO ELIGIBLE HOLDERS REGARDING THE EXPIRATION OF THE EXCHANGE OFFER From: SINGULAR GENOMICS SYSTEMS, INC. |
|
| July 25, 2022 |
Form of Email to Eligible Holders Confirming Acceptance of Eligible Option(s). Exhibit (a)(1)(H) FORM OF EMAIL TO ELIGIBLE HOLDERS CONFIRMING ACCEPTANCE OF ELIGIBLE OPTION(S) From: SINGULAR GENOMICS SYSTEMS, INC. |
|
| July 25, 2022 |
Form of Email Confirming Receipt of Notice of Withdrawal of Election Form. Exhibit (a)(1)(F) FORM OF EMAIL CONFIRMING RECEIPT OF NOTICE OF WITHDRAWAL OF ELECTION FORM From: SINGULAR GENOMICS SYSTEMS, INC. |
|
| July 25, 2022 |
Stock Option Exchange Singular Genomics July 2022 Exhibit (a)(1)(K) Stock options are a critical component of our compensation philosophy, the focal point of which is to encourage our employees and consultants to build long-term stockholder value. |
|
| July 25, 2022 |
Form of Email Confirming Receipt of Election Form. Exhibit (a)(1)(E) FORM OF EMAIL CONFIRMING RECEIPT OF ELECTION FORM From: SINGULAR GENOMICS SYSTEMS, INC. |
|
| July 25, 2022 |
Form of Expiration Notice Email. Exhibit (a)(1)(J) FORM OF EXPIRATION NOTICE EMAIL From: SINGULAR GENOMICS SYSTEMS, INC. |
|
| July 19, 2022 |
Sales Agreement dated as of July 19, 2022, by and between the Registrant and Cowen and Company, LLC. Exhibit 1.2 Execution Version SINGULAR GENOMICS SYSTEMS, INC. $100,000,000 COMMON STOCK SALES AGREEMENT July 19, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Singular Genomics Systems, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. |
|
| July 19, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Singular Genomics Systems, Inc. |
|
| July 19, 2022 |
Form of Indenture with respect to the Securities. Exhibit 4.5 INDENTURE between SINGULAR GENOMICS SYSTEMS, INC. as Issuer and [TRUSTEE] as Trustee Dated as of , 20 Providing for the Issuance of Debt Securities in Series SINGULAR GENOMICS SYSTEMS, INC. Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec. 312(c) 701 Sec. 314(a) 703 ( |
|
| July 19, 2022 |
As filed with the Securities and Exchange Commission on July 19, 2022 Table of Contents As filed with the Securities and Exchange Commission on July 19, 2022 Registration No. |
|
| July 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Comm |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Commi |
|
| May 10, 2022 |
Singular Genomics Systems, Inc. Reports Recent Highlights and First Quarter 2022 Financial Results Singular Genomics Systems, Inc. Reports Recent Highlights and First Quarter 2022 Financial Results La Jolla, CA, May 10, 2022 ? Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the quarter en |
|
| May 10, 2022 |
DocuSign Envelope ID: FC2CC128-9822-4855-A001-C19E6B8CA968 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 19 day of January, 2022, between ARE-10933 NORTH TORREY PINES, LLC, a Delaware limited liability company (?Landlord?), and SINGULAR GENOMICS SYSTEMS, INC. |
|
| May 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 SIN |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Commi |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Com |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin |
|
| March 14, 2022 |
As filed with the Securities and Exchange Commission on March 14, 2022 As filed with the Securities and Exchange Commission on March 14, 2022 Registration No. |
|
| March 14, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Singular Genomics Systems Inc. |
|
| March 14, 2022 |
Exhibit 4.2 DESCRIPTION OF SINGULAR GENOMICS SYSTEMS, INC.?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock, par value $0.0001 per share, of Singular Genomics Systems, Inc. (?us,? ?our,? ?we,? or the ?Company?), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1 |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40443 SINGULAR GENOMI |
|
| March 2, 2022 |
Singular Genomics Systems, Inc. Reports Recent Highlights, Fourth Quarter and Full Year 2021 Financial Results La Jolla, CA, March 2, 2022 ? Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for t |
|
| March 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Comm |
|
| February 14, 2022 |
EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| February 14, 2022 |
OMIC / Singular Genomics Systems, Inc. / Revelation Alpine, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82933R100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 14, 2022 |
OMIC / Singular Genomics Systems, Inc. / Glezer Eli N. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Singular Genomics Systems, Inc. |
|
| February 14, 2022 |
OMIC / Singular Genomics Systems, Inc. / Spaventa Andrew - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Singular Genomics Systems, Inc. |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ???)* Singular Genomics Systems, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 82933R100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to des |
|
| January 26, 2022 |
EX-3.1 2 omic-ex31.htm EX-3.1 SINGULAR GENOMICS SYSTEMS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A COMMON STOCK EQUIVALENT CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151(g) OF THE DELAWARE GENERAL CORPORATION LAW Singular Genomics Systems, Inc., a Delaware corporation (the “Company”), in accordance with the provisions of Section 103 of the Delaware Gen |
|
| January 26, 2022 |
EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (including the schedules, annexes and exhibits hereto, this ?Agreement?), dated as of January 26, 2022, is entered into by and among Singular Genomics Systems, Inc. |
|
| January 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (C |
|
| January 20, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (C |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (C |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Co |
|
| January 6, 2022 |
Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D., to Board of Directors EX-99.1 2 d253895dex991.htm EX-99.1 Exhibit 99.1 Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D., to Board of Directors La Jolla, CA, January 6, 2022 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Ma |
|
| January 4, 2022 |
OMIC / Singular Genomics Systems, Inc. / Domain Partners IX, L.P. - SCHEDULE 13G Passive Investment SC 13G 1 s13g123121-singular.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Singular Genomics Systems, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securitie |
|
| December 16, 2021 |
EX-99.1 2 omic-ex991.htm EX-99.1 Singular Genomics Launches the G4 Sequencing Platform – Next-generation sequencing platform will provide up to three times more data output per hour than other benchtop instruments, while offering flexible run capacity – La Jolla, CA, December 16, 2021 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and |
|
| December 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) ( |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) ( |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 |
|
| November 9, 2021 |
Singular Genomics Systems, Inc. Reports Recent Highlights and Third Quarter Financial Results EX-99.1 2 omic-ex991.htm EX-99.1 Singular Genomics Systems, Inc. Reports Recent Highlights and Third Quarter Financial Results La Jolla, CA, November 9, 2021 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company focused on delivering genomic technologies for the advancement of science and medicine, today highlighted recent corporate achievements and reported financial results for the third q |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (C |
|
| November 9, 2021 |
EX-10.1 2 omic-ex101.htm EX-10.1 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (“Bank”), and the borrower listed on Schedule I hereto (“Borrower”). The parties agree as follows: Recitals A. Bank and Borrower have entered into that certa |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2021 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction o |
|
| August 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2021 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Co |
|
| August 25, 2021 |
As filed with the Securities and Exchange Commission on August 25, 2021 Table of Contents As filed with the Securities and Exchange Commission on August 25, 2021 Registration No. |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Co |
|
| August 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Com |
|
| August 3, 2021 |
Singular Genomics Systems, Inc. Announces Second Quarter Financial Results and Operations Update Exhibit 99.1 Singular Genomics Systems, Inc. Announces Second Quarter Financial Results and Operations Update La Jolla, CA, August 3, 2021 ? Singular Genomics Systems, Inc., a company focused on delivering genomic technologies for the advancement of science and medicine, today reported its second quarter 2021 financial results and highlighted recent operating and corporate achievements. Investors |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 SING |
|
| June 3, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| June 1, 2021 |
Amended and Restated Bylaws of Registrant. EX-3.2 3 d171098dex32.htm EX-3.2 Exhibit 3.2 Singular Genomics Systems, Inc. Amended and Restated Bylaws (amended and restated on May 19, 2021 and effective as of the closing of this corporation’s initial public offering) Table of Contents Page Article I Stockholders 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Ad |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40443 81-2948451 (State or other jurisdiction of incorporation) (Commi |
|
| June 1, 2021 |
Amended and Restated Certificate of Incorporation of Registrant EX-3.1 2 d171098dex31.htm EX-3.1 Exhibit 3.1 Singular Genomics Systems, Inc. Amended and Restated Certificate of Incorporation Singular Genomics Systems, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is Singular Genomics Systems, Inc., which was the name under which the corporation was originally inco |
|
| June 1, 2021 |
Exhibit 99.1 Singular Genomics Systems, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares La Jolla, CA, June 1, 2021 ? Singular Genomics Systems, Inc. (?Singular Genomics?), a company focused on delivering genomic technologies for the advancement of science and medicine, today announced the closing of its initial public offeri |
|
| May 28, 2021 |
10,200,000 Shares Common Stock Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-255912 Registration No. 333-256522 P R O S P E C T U S 10,200,000 Shares Common Stock This is the initial public offering of shares of common stock of Singular Genomics Systems, Inc. We are offering 10,200,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial |
|
| May 27, 2021 |
As filed with the Securities and Exchange Commission on May 27, 2021 Registration No. |
|
| May 26, 2021 |
As filed with the Securities and Exchange Commission on May 26, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 SINGULAR GENOMICS SYSTEMS, INC. (Exact name of Registrant as specified in its charter) Delaware 3826 81-2948451 (State or other jurisdiction of incorporation or organizati |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Singular Genomics Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2948451 (State of incorporation or organization) (I.R.S. Employer Identification No.) 10931 N. Tor |
|
| May 24, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on May 24, 2021. |
|
| May 24, 2021 |
May 24, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 24, 2021 |
Management Cash Incentive Plan. EX-10.13 10 d240097dex1013.htm EX-10.13 Exhibit 10.13 SINGULAR GENOMICS SYSTEMS, INC. MANAGEMENT CASH INCENTIVE PLAN ARTICLE 1. BACKGROUND AND PURPOSE 1.1 Effective Date. This Plan became effective upon its adoption by the Committee and is not subject to approval by the Company’s stockholders. 1.2 Purpose of the Plan. The Plan is intended to provide Participants with the possibility of earning inc |
|
| May 24, 2021 |
Specimen common stock certificate of the Registrant. EX-4.1 Exhibit 4.1 SEE REVERSE FOR IMPORTANT NOTICE REGARDING OWNERSHIP AND TRANSFER RESTRICTIONS AND CERTAIN OTHER INFORMATION INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP 82933R 10 0 COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS SPECIMEN FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK $0.0001 PAR VALUE, OF SINGULAR GENOMICS SYSTEMS, INC. transferable on the books of the |
|
| May 24, 2021 |
Amended and Restated Bylaws of Registrant. EXHIBIT 3.4 Singular Genomics Systems, Inc. Amended and Restated Bylaws (amended and restated on May 19, 2021 and effective as of the closing of this corporation’s initial public offering) Table of Contents Page Article I Stockholders 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 3 1.8 Voting and Proxi |
|
| May 24, 2021 |
2021 Equity Incentive Plan and forms of agreements thereunder. EX-10.3 EXHIBIT 10.3 SINGULAR GENOMICS SYSTEMS, INC. 2021 EQUITY INCENTIVE PLAN (AS ADOPTED ON MAY 19, 2021) SINGULAR GENOMICS SYSTEMS, INC. 2021 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately, although no Awards may be granted under the Plan prior to the IPO Date. The purpose of the Plan is to promote the long-term success of the Company |
|
| May 24, 2021 |
May 24, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Jeffrey Gabor Ibolya Ignat Lynn Dicker Re: Singular Genomics Systems, Inc. Registration Statement on Form S-1 File No. 333-255912 Request for Acceleration of Effective Date Requested Date: Wednesday, May 26, 2021 Requested Time: 4:00 P.M. |
|
| May 24, 2021 |
EXHIBIT 10.1 [AMENDED AND RESTATED]1 INDEMNITY AGREEMENT THIS [AMENDED AND RESTATED] INDEMNITY AGREEMENT (this “Agreement”) dated as of , is made by and between Singular Genomics Systems, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS: A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. |
|
| May 24, 2021 |
Amended and Restated Certificate of Incorporation of Registrant. EXHIBIT 3.2 Singular Genomics Systems, Inc. Amended and Restated Certificate of Incorporation Singular Genomics Systems, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is Singular Genomics Systems, Inc., which was the name under which the corporation was originally incorporated. The date of the filing |
|
| May 24, 2021 |
EX-10.14 11 d240097dex1014.htm EX-10.14 Exhibit 10.14 SINGULAR GENOMICS SYSTEMS, INC. EXECUTIVE SEVERANCE PLAN 1. Purpose of the Plan The purpose of the Plan is to provide for the payment of severance benefits to certain eligible employees of the Company in the event such employees are subject to certain qualifying employment terminations. This Plan shall supersede any and all prior separation, se |
|
| May 24, 2021 |
2021 Employee Stock Purchase Plan. EXHIBIT 10.4 SINGULAR GENOMICS SYSTEMS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN (AS ADOPTED ON MAY 19, 2021) SINGULAR GENOMICS SYSTEMS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN SECTION 1. PURPOSE OF THE PLAN. The Board adopted the Plan effective as of the IPO Date. The purpose of the Plan is to provide Eligible Employees with an opportunity to increase their interest in the success of the Company by |
|
| May 24, 2021 |
Form of Underwriting Agreement. EX-1.1 2 d240097dex11.htm EX-1.1 Exhibit 1.1 Singular Genomics Systems, Inc. [•] Shares of Common Stock, par value $0.0001 per share Form of Underwriting Agreement [•], 2021 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC BofA Securities, Inc. Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New Y |
|
| May 12, 2021 |
As filed with the Securities and Exchange Commission on May 12, 2021. Table of Contents As filed with the Securities and Exchange Commission on May 12, 2021. |
|
| May 12, 2021 |
May 12, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Alan Campbell Jeffrey Gabor Re: Singular Genomics Systems, Inc. CIK No. 0001850906 Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted April 26, 2021 Registration Statement on Form S-1 Filed May 7, 2021 Registration Statement No: |
|
| May 7, 2021 |
EX-10.8 10 d240097dex108.htm EX-10.8 Exhibit 10.8 SINGULAR GENOMICS SYSTEMS, INC. December 17, 2019 Andrew Spaventa Dear Drew: SINGULAR GENOMICS SYSTEMS, INC. (the “Company”) is pleased to confirm the amended terms of your employment with the Company, as follows: 1. Position. Your title will continue to be Chief Executive Officer, President and Chairman of the Board. This is a full-time position. |
|
| May 7, 2021 |
Bylaws of Registrant, as currently in effect EX-3.3 3 d240097dex33.htm EX-3.3 Exhibit 3.3 BYLAWS OF SINGULAR GENOMICS SYSTEMS, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS Page ARTICLE I OFFICES 1 1.1 Registered Office 1 1.2 Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Location 1 2.2 Timing 1 2.3 Notice of Meeting 1 2.4 Stockholders’ Records 1 2.5 Special Meetings 2 2.6 Notice of Meeting 2 2.7 Business Transacted at Special Meeting |
|
| May 7, 2021 |
EX-10.6 8 d240097dex106.htm EX-10.6 Exhibit 10.6 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 26th day of June, 2020, between ARE-SD REGION NO. 27, LLC, a Delaware limited liability company (“Landlord”), and SINGULAR GENOMICS SYSTEMS, INC., a Delaware corporation (“Tenant”). Building: 3010 Science Park Road, San Diego, California Premises: The entire Building, containing approx |
|
| May 7, 2021 |
Offer Letter, dated September 25, 2019, by and between the Registrant and Dalen Meeter. Exhibit 10.10 September 25, 2019 Dalen Meeter Dear Dalen: SINGULAR GENOMICS SYSTEMS, INC. (the “Company”) is pleased to offer you employment on the following terms: 1. Position. Your initial title will be Vice President, Finance. This is a full-time position. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-t |
|
| May 7, 2021 |
Exhibit 10.9 SINGULAR GENOMICS SYSTEMS, INC. December 17, 2019 Dr. Eli Glezer Dear Eli: SINGULAR GENOMICS SYSTEMS, INC. (the “Company”) is pleased to confirm the amended terms of your employment with the Company, as follows: 1. Position. You will continue to serve as the Company’s Chief Scientific Officer. This is a full-time position. In this position, you will be responsible for leading the Comp |
|
| May 7, 2021 |
Power of Attorney (included on signature page). Table of Contents As filed with the Securities and Exchange Commission on May 7, 2021. |
|
| May 7, 2021 |
Sublease, dated June 15, 2020, by and between the Registrant and Gossamer Bio, Inc. Exhibit 10.7 SUBLEASE 1. PARTIES. This Sublease, dated June 15, 2020 (“Effective Date”) is made between GOSSAMER BIO, INC., a Delaware corporation (“Sublessor”), and SINGULAR GENOMICS SYSTEMS, INC., a Delaware corporation (“Sublessee”). 2. MASTER LEASE. Sublessor is the lessee under that certain Lease Agreement dated November 19, 2019, (the “Master Lease”) attached as Exhibit ‘B’, wherein ARE-SD R |
|
| May 7, 2021 |
Exhibit 10.5 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 1st day of November, 2017, between ARE-10933 NORTH TORREY PINES, LLC, a Delaware limited liability company (“Landlord”), and SINGULAR GENOMICS SYSTEMS, INC., a Delaware corporation (“Tenant”). Building: 10931 N. Torrey Pines Road, San Diego, California Premises: That portion of the Project, initially containing approxima |
|
| May 7, 2021 |
Series B Preferred Stock Warrant, as amended. EX-4.3 5 d240097dex43.htm EX-4.3 Exhibit 4.3 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTAN |
|
| May 7, 2021 |
EX-4.2 4 d240097dex42.htm EX-4.2 Exhibit 4.2 SINGULAR GENOMICS SYSTEMS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT June 27, 2019 1 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 3 2.1 Request for Registration 3 2.2 Company Registration 5 2.3 Form S-3 Registration 6 2.4 Obligations of the Company 8 2.5 Information from Holder 9 2.6 Expenses of Registration 9 |
|
| May 7, 2021 |
Loan Agreement, dated November 19, 2019, by and between the Registrant and Silicon Valley Bank. Exhibit 10.11 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of November 19, 2019 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and SINGULAR GENOMICS SYSTEMS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows |
|
| May 7, 2021 |
Exhibit 10.12 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. EXCLUSIVE LICENSE AGREEMENT AGREEMENT, dated August 12, 2016 (the ?Effective Date?), between THE TRUSTEES OF COLUMBIA UNIVERSITY IN TH |
|
| May 7, 2021 |
2016 Stock Plan and forms of agreements thereunder. EX-10.2 6 d240097dex102.htm EX-10.2 Exhibit 10.2 SINGULAR GENOMICS SYSTEMS, INC. 2016 STOCK PLAN ADOPTED ON SEPTEMBER 19, 2016 TABLE OF CONTENTS Page SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. ADMINISTRATION 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. ELIGIBILITY 1 (a) General Rule 1 (b) Ten-Percent Stockholders 1 SECTION 4. STOCK SUBJEC |
|
| May 7, 2021 |
Amended and Restated Certificate of Incorporation of Registrant, as currently in effect EX-3.1 2 d240097dex31.htm EX-3.1 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF SINGULAR GENOMICS SYSTEMS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Singular Genomics Systems, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation L |
|
| April 26, 2021 |
SINGULAR GENOMICS SYSTEMS, INC. December 17, 2019 EX-10.9 5 filename5.htm Exhibit 10.9 SINGULAR GENOMICS SYSTEMS, INC. December 17, 2019 Dr. Eli Glezer Dear Eli: SINGULAR GENOMICS SYSTEMS, INC. (the “Company”) is pleased to confirm the amended terms of your employment with the Company, as follows: 1. Position. You will continue to serve as the Company’s Chief Scientific Officer. This is a full-time position. In this position, you will be responsi |
|
| April 26, 2021 |
EX-10.10 6 filename6.htm Exhibit 10.10 September 25, 2019 Dalen Meeter Dear Dalen: SINGULAR GENOMICS SYSTEMS, INC. (the “Company”) is pleased to offer you employment on the following terms: 1. Position. Your initial title will be Vice President, Finance. This is a full-time position. While you render services to the Company, you will not engage in any other employment, consulting or other business |
|
| April 26, 2021 |
SINGULAR GENOMICS SYSTEMS, INC. December 17, 2019 EX-10.8 4 filename4.htm Exhibit 10.8 SINGULAR GENOMICS SYSTEMS, INC. December 17, 2019 Andrew Spaventa Dear Drew: SINGULAR GENOMICS SYSTEMS, INC. (the “Company”) is pleased to confirm the amended terms of your employment with the Company, as follows: 1. Position. Your title will continue to be Chief Executive Officer, President and Chairman of the Board. This is a full-time position. In this posit |
|
| April 26, 2021 |
SINGULAR GENOMICS SYSTEMS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT June 27, 2019 EX-4.2 2 filename2.htm Exhibit 4.2 SINGULAR GENOMICS SYSTEMS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT June 27, 2019 1 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 3 2.1 Request for Registration 3 2.2 Company Registration 5 2.3 Form S-3 Registration 6 2.4 Obligations of the Company 8 2.5 Information from Holder 9 2.6 Expenses of Registration 9 2.7 Del |
|
| April 26, 2021 |
EX-4.3 3 filename3.htm Exhibit 4.3 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFA |
|
| April 26, 2021 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on April 26, 2021 as Amendment No. |
|
| April 26, 2021 |
EX-10.12 8 filename8.htm Exhibit 10.12 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. EXCLUSIVE LICENSE AGREEMENT AGREEMENT, dated August 12, 2016 (the “Effective Date”), between THE TRUSTEES OF |
|
| April 26, 2021 |
EX-10.11 7 filename7.htm Exhibit 10.11 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of November 19, 2019 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and SINGULAR GENOMICS SYSTEMS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The |
|
| April 26, 2021 |
DRSLTR 1 filename1.htm SILICON VALLEY ANN ARBOR BEIJING BOSTON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO SINGAPORE April 26, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Alan Campbell Jeffrey Gabor Re: Singular Genomics Systems, Inc. Draft Registration Statement on Form S-1 Submitted March 22, 20 |
|
| March 22, 2021 |
SINGULAR GENOMICS SYSTEMS, INC. 2016 STOCK PLAN ADOPTED ON SEPTEMBER 19, 2016 EX-10.2 4 filename4.htm Exhibit 10.2 SINGULAR GENOMICS SYSTEMS, INC. 2016 STOCK PLAN ADOPTED ON SEPTEMBER 19, 2016 TABLE OF CONTENTS Page SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. ADMINISTRATION 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. ELIGIBILITY 1 (a) General Rule 1 (b) Ten-Percent Stockholders 1 SECTION 4. STOCK SUBJECT TO PLAN 2 |
|
| March 22, 2021 |
BYLAWS OF SINGULAR GENOMICS SYSTEMS, INC. (A DELAWARE CORPORATION) EX-3.3 3 filename3.htm Exhibit 3.3 BYLAWS OF SINGULAR GENOMICS SYSTEMS, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS Page ARTICLE I OFFICES 1 1.1 Registered Office 1 1.2 Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Location 1 2.2 Timing 1 2.3 Notice of Meeting 1 2.4 Stockholders’ Records 1 2.5 Special Meetings 2 2.6 Notice of Meeting 2 2.7 Business Transacted at Special Meeting 2 2.8 Quo |
|
| March 22, 2021 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on March 19, 2021. |
|
| March 22, 2021 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF SINGULAR GENOMICS SYSTEMS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Singular Genomics Systems, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: FIRST: |
